JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung?

Cancer 1984 Februrary 16
A 34-year-old woman with typical chronic myelogenous leukemia was treated with daily busulfan (total dose, 1600 mg approximately) from July 1978 to June 1981. In February 1981, she noticed a progressive deterioration of her clinical status, characterized by increasing dyspnea and productive cough. In July 1981, an open lung biopsy revealed pulmonary alveolar proteinosis. The patient died of progressive respiratory failure in August 1981. The association between chronic myelogenous leukemia and pulmonary alveolar proteinosis is briefly reviewed. The report discusses the possible etiologic role of busulfan therapy in the development of pulmonary alveolar proteinosis.

Full text links

Management of Latent Tuberculosis Infection.JAMA 2023 January 20
Misdiagnosis in the Emergency Department: Time for a System Solution.JAMA 2023 January 28

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app